Co-Delivery of Paclitaxel and Thymoquinone via Polymeric Nanoparticles Induces Apoptosis and Suppresses Epithelial-Mesenchymal Transition Through Wnt/β-Catenin Signaling in MCF-7 Breast Cancer Cell Line

Cancer is a disease of uncontrolled growth, but it is also a disease of movement. The most dangerous aspect of breast cancer is not just the primary tumor, but its ability to spread to other parts of the body. To do this, cancer cells often undergo a transformation where they lose their sticky, stationary nature and become slippery, mobile invaders. Scientists call this process the epithelial-to-mesenchymal transition. It is a biological switch that allows cells to detach from a tumor, travel through the bloodstream, and start new colonies elsewhere. At the same time, many cancer cells develop defenses that pump out chemotherapy drugs before they can work, making standard treatments less effective over time. Finding a way to stop both the spread and the resistance of these cells is a central goal in modern medicine.

Researchers at Guru Jambheshwar University of Science and Technology and Maharshi Dayanand University in India have explored a new approach to this problem by combining two very different substances into a single, tiny delivery system. One substance is paclitaxel, a powerful chemotherapy drug derived from the bark of the Pacific yew tree that stops cells from dividing. The other is thymoquinone, a natural compound found in black cumin seeds, which has been used for centuries in traditional medicine and is known to trigger cell death in cancer. While both have shown promise on their own, they are difficult to dissolve in water and can be toxic to healthy cells when delivered in their raw form. The researchers asked whether wrapping these two drugs together inside a microscopic polymer shell could make them work better together than apart, and whether this combination could specifically turn off the biological switch that allows cancer cells to spread.

To test this, the team created tiny spheres, known as polymeric nanoparticles, using a method called nanoprecipitation. They mixed the drugs with a special polymer, Eudragit RS 100, which forms a protective shell around the medicine. They also added a surfactant to keep the particles stable and prevent them from clumping together. The resulting nanoparticles were incredibly small, measuring roughly 134 when loaded with both drugs, a size small enough to potentially accumulate in tumors. The team confirmed that the drugs were successfully trapped inside these shells and that they were released slowly over time, rather than all at once. This slow release is crucial because it keeps the drug concentration high at the tumor site for longer, while the polymer shell protects the drugs from breaking down too early in the body.

When the researchers tested these nanoparticles on MCF-7 breast cancer cells in a laboratory dish, the results were striking. The combination of the two drugs inside the nanoparticles killed significantly more cancer cells than either drug alone, or even the two drugs mixed together without the nanoparticle carrier. The researchers calculated a synergy score that confirmed the two drugs were working together to amplify each other's effects, rather than just adding their individual impacts. The nanoparticles were able to stop the cancer cells from growing and forming new colonies, effectively cutting off the tumor's ability to regenerate. In tests designed to measure how well the cells could move, the combined treatment reduced migration by about 91 percent, suggesting a powerful ability to stop the cancer from spreading.

The study went deeper to understand how this happened. By looking at the cells under a microscope and using flow cytometry, a technique that counts and sorts cells based on their properties, the researchers saw that the nanoparticles forced the cancer cells into a state of programmed death, known as apoptosis. The cells did not just burst open; they followed a controlled path of self-destruction. The team observed that the cells got stuck in a specific phase of their life cycle, unable to divide, while their DNA began to fragment. This dual action of stopping division and triggering death was confirmed by observing the nuclei of the cells, which showed the classic signs of apoptosis, such as shrinking and breaking apart.

Perhaps the most significant finding was how the treatment affected the biological pathways that drive cancer spread. The researchers analyzed the genes and proteins inside the cells and found that the nanoparticle treatment turned down the activity of a key signaling pathway known as Wnt/β-catenin. This pathway acts as a master regulator for the epithelial-to-mesenchymal transition. When this pathway is active, it tells the cell to become mobile and invasive. The treatment successfully lowered the levels of the proteins that drive this movement, such as N-cadherin and vimentin, while boosting the levels of E-cadherin, a protein that helps cells stick together and stay in place. This reversal of the molecular switch suggests that the nanoparticles not only kill the cancer cells but also strip them of their ability to migrate and invade other tissues.

The study concludes that delivering paclitaxel and thymoquinone together inside these polymeric nanoparticles creates a powerful therapeutic effect against breast cancer cells in the lab. The combination induces cell death, stops the cells from dividing, and reverses the biological changes that allow cancer to spread. While these results are currently limited to laboratory experiments on cells and have not yet been tested in humans, the findings offer a promising blueprint for a new type of treatment. By using a single carrier to deliver two complementary drugs, this approach could potentially overcome the resistance and mobility that make breast cancer so difficult to treat, providing a more effective way to manage the disease in the future.